HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kinetin license

This article was originally published in The Rose Sheet

Executive Summary

Global non-exclusive licensing agreement between Senetek and Danish health care company Ferrosan will result in expanded mass market distribution of Senetek's Kinetin anti-aging technology, firm says. Ferrosan plans to market a line of skin care products with Kinetin under its Imedeen brand of oral skin care supplements, according to the company. Under the agreement, Ferrosan will manufacture and market the range in the mass market, as well as prestige, natural product and direct-to-consumer channels globally. Senetek recently amended a licensing agreement with Revlon that gave the cosmetics firm exclusive use of Kinetin in the mass market; the ingredient is used in Revlon's Almay Kinetin line, which bowed in 2001 (1"The Rose Sheet" March 19, 2001, p. 7)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel